The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5–6, 2024 ( http://www.cvot.org ).

中文翻译：

---

2023 年 CVOT 峰会报告：新的心血管、肾脏和代谢结果

第九届心血管结局试验（CVOT）峰会：心血管、肾脏和代谢结局大会于2023年11月30日至12月1日以虚拟方式举行。这次参考大会为近期完成的结局试验提供了深入讨论和交流的平台包括达格列净 (DAPA-MI)、司马鲁肽 (SELECT 和 STEP-HFpEF) 和 bempedoic Acid (CLEAR Outcomes)，以及它们在降低主要不良心血管事件 (MACE) 风险、改善代谢结果和治疗肥胖方面所取得的进展 -相关的射血分数保留的心力衰竭（HFpEF）。由内分泌学家、糖尿病学家、心脏病学家、肾病学家和初级保健医生组成的广大观众参与了关于糖尿病、心力衰竭 (HF) 和慢性肾病 (CKD) 心血管疾病 (CVD) 管理指南更新的在线讨论；1 型糖尿病 (T1D) 及其合并症的治疗进展；SGLT2 抑制剂和非类固醇盐皮质激素受体拮抗剂 (nsMRA) 治疗 CKD 的进展；以及 GLP-1 和双 GIP/GLP-1 受体激动剂治疗肥胖症的进展。还探讨了糖尿病和肥胖与非酒精性脂肪性肝炎（NASH；代谢功能障碍相关性脂肪性肝炎，MASH）和癌症的关联以及这些并发症的可能治疗方法。人们普遍认为慢性病的治疗对所有患者都同样有效。然而，正如峰会所讨论的那样，这一假设可能并不正确。因此，重要的是让来自不同种族和民族的患者参加临床试验，分析患者报告的结果以评估治疗效果，并开发创新方法，为那些受益最大、副作用最小的人量身定制药物。成功管理糖尿病和包括痴呆在内的合并症的其他关键包括使用连续血糖监测 (CGM) 技术和实施适当的医患沟通策略。第十届心血管结果试验峰会将于 2024 年 12 月 5 日至 6 日以虚拟方式举行 (http://www.cvot.org)。